CO HB1214

Governor directs the Colorado Consortium for Prescription Drug Abuse Prevention to study barriers to using abuse-deterrent opioid analgesic drugs to reduce opioid abuse and diversion.

Consortium must report findings to the Public Health Care and Human Services Committee, Health, Insurance, and Environment Committee of the House, and Health and Human Services Committee of the Senate by January 15, 2017.

General fund moneys cannot be used to implement this section.

Abuse-deterrent opioid analgesic drug product is defined as a brand or generic opioid drug approved by the FDA with abuse-deterrence labeling claims indicating meaningful reduction in abuse.

Opioid analgesic drug product means drugs in the opioid class prescribed for moderate to severe pain in immediate or extended release forms, potentially combined with other substances.